NCT06690177Phase 2Not yet recruiting

Controlled Study, Performed to Evaluate the Safety and Efficacy of EscharEx and Its Placebo (Gel Vehicle) Compared to Non-surgical Standard of Care in Participants With Venous Leg Ulcers (VLU)

Study sponsor: MediWound Ltd · MDWD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-11-04Estimated
Enrollment · participants45Estimated
Source updated2026-10-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence (number of patients) of target wound related AEs throughout the trial Description: The endpoint will assess number of patients, in each arm, with reported local (target wound related) AEs Time frame: Throughout the study (week 2- week 15) Measure: Number of patients with Clinically significant changes in vital signs during the Daily Visits Period, Description: Number of patients with Clinically significant changes in vital signs Time frame: Weeks 2-3 (14 days) Measure: Number of patients with Clinically significant changes in clinical laboratory parameters Description: Number of patients with Clinically significant changes in clinical laboratory parameters Time frame: Weeks 2-3 (14 days) Measure: Time to complete wound closure Description: The outcome will assess time to reaching complete wound closure Time frame: Weeks 2-15 Measure: Incidence of complete wound closure Description: The outcome will assess number of patients reaching complete wound closure Time frame: 2-15 weeks. After: Measure: Incidence (number of patients) of systemic and local adverse events (AEs) throughout the trial Description: The endpoint will assess number of patients, in each arm, with reported systemic and local AEs Time frame: Throughout the study (week 2- week 17) Measure: Number of patients with Clinically significant changes in vital signs during the Daily Visits Period, Description: Number of patients with Clinically significant changes in vital signs Time frame: Weeks 2-3 (14 days) Measure: Number of patients with Clinically significant changes in clinical laboratory parameters Description: Number of patients with Clinically significant changes in clinical laboratory parameters Time frame: Weeks 2-3 (14 days) Measure: Time to complete wound closure Description: The outcome will assess time to reaching complete wound closure Time frame: Weeks 2-17 Measure: Incidence of complete wound closure Description: The outcome will assess number of patients reaching complete wound closure Time frame: 2-17 weeks.

Primary completion date changed

Before: 30 Dec 2027. After: 4 Nov 2028.

Check registry source